Objective: The objective of this study was to evaluate the safety and efficacy of early amino acid (early AA) administration in very low birth weight (VLBW) infants.
Introduction
Despite advances in the care of very low birth weight (VLBW) infants, postnatal growth restriction continues to be a problem for these infants and their caretakers. 1, 2 Postnatal growth restriction can occur because of inadequate nutritional intake, increased energy demands with concomitant protein deficits and administration of drugs (diuretics and steroids). [3] [4] [5] [6] Malnutrition at a vulnerable period of brain development adversely influences long-term developmental outcomes through decreased numbers of brain cells. [7] [8] [9] Malnutrition directly affects the child's energy level, rate of motor development and rate of growth, thus interfering with neurodevelopment. 8 In addition, decreased availability of energy and nutrients may lead to reduced recovery from acute and chronic lung disease. 10 Protein is an important component of adequate nutrition as it provides essential amino acids (AAs) required for protein synthesis. Preterm infants have a very rapid rate of growth and protein accretion. 2 Therefore, the administration of dietary protein is important in the preterm infants for normal growth and development.
Very low birth weight infants are dependent on externally administered nutrients after birth. Both fat tissue and glycogen levels are limited; consequently, without adequate exogenous nutrient supplies, protein breakdown will increase in these infants, resulting in a catabolic state. 11, 12 One of the mechanisms for poor growth in the initial days of life in preterm infants is the delay in introduction of protein. VLBW infants who receive only glucose experience protein losses of 0.5 to 1 g kg À1 per day. 13 Therefore, a delay in the administration of AAs may contribute to growth delay. Administration of AAs within the first few hours after birth may reduce protein deficit and decrease the amount of growth failure. 3 There is now evidence that VLBW infants can tolerate AA solutions even during the first days of life. 13 However, specific nutritional requirements have yet to be defined. Few studies have assessed the outcome of early administration of protein in preterm infants. The objective of this study was to evaluate the safety and efficacy of early AA administration in the form of parenteral nutrition (PN) to VLBW preterm infants (<1500 g).
Methods

Study population
This study was a pre-and post-intervention, comparative study of the timing of AA administration for infants admitted to the neonatal intensive care unit (NICU) at Johns Hopkins Hospital between January 2007 and July 2008. All preterm infants with birth weights of <1500 g were evaluated for this study. Infants who were transferred into the NICU after 24 h of life or were transferred to an outside institution before achieving full feeds were excluded. The institutional review board of the Johns Hopkins Medical Institutions approved the study.
Procedure
After a multidisciplinary review of the current literature, a protocol was implemented for the initiation of AA solution shortly after admission (early AA). Early AA was given in the form of PN that consisted of 10% dextrose, 2.2 g of amino acids per kg per day and 29 mg kg À1 per day of elemental calcium. Additional fluids were given to maintain an adequate glucose infusion rate and hydration. The standard practices in the NICU before the implementation of the new protocol included initiation of intravenous fluids with a 5 or 10% dextrose solution initially upon admission with conversion to PN within the first 48 h of life (standard). In both time periods, enteral nutrition was started at the discretion of the neonatologist who cared for the infant. This generally occurred when the infants showed cardiovascular and respiratory stability. Enteral feeds were advanced as tolerated to a level of 140 ml kg À1 per day of 24 kcal ounce À1 or an equivalent of 110 kcal per day of breastmilk or formula.
Data collection
The pre-intervention period was defined as 9 months before the protocol change and the post-intervention period was 10 months after the introduction of early AA. The primary outcome variables were the time to regain birth weight and the day of life full feeds were achieved (140 ml kg À1 per day of 24 kcal ounce À1 or equivalent of 110 kcal kg À1 per day). Information, including gestational age, birth weight, Score for Neonatal Acute Physiology, Version II and the day of life feeds were initiated, were also collected. Secondary outcomes included weight at 32 weeks post-menstrual age, total days of PN, length of hospitalization, survival to hospital discharge and adverse clinical outcomes. Adverse outcomes included chronic lung disease (defined as oxygen requirement beyond 28 days of life), cholestatic jaundice (defined as direct bilirubin >2 mg per 100 ml), necrotizing enterocolitis (NEC) and confirmed sepsis (defined as identification of bacterial or fungal pathogen cultured in the blood, urine or cerebrospinal fluid after 7 days of life).
Statistical analysis
The groups were compared using non-parametric methods (chi-square) for categorical variables and means (95% confidence intervals) for continuous variables. A P-value of <0.05 was considered significant. Data were analyzed using SPSS version 16 (SPSS, Inc, Chicago, IL, USA).
Results
In all, 179 infants met initial qualifications of birth weight and admission within 24 h of life for study entry. Out of the total, 16 infants died within the first 2 weeks of life: 14 died within 72 h, one of respiratory failure on day 12, and the remaining infant died of NEC on day 12. Six infants were transferred to other facilities before reaching full feeds, and thus had incomplete outcome data. Outcomes were examined in 81 infants in the preintervention standard PN period and in 75 infants in the postintervention early AA period (Figure 1 ). Four infants, who were in the post-intervention period but never received the early AA, were maintained in their group to accurately reflect the effect of the practice change. Analysis was carried out with these four infants excluded and did not affect the results.
Patient characteristics, including gestational age, birth weight and Score for Neonatal Acute Physiology, Version II, were similar in the two groups (Table 1) . Six infants in each group were small for gestational age at birth. Late mortality was also similar between groups, occurring at 15 to 238 days of life, predominantly because of cardiovascular and respiratory complications. One infant in the post-intervention group died of NEC on day 35, but was one of the four infants who did not receive early AA solution. A comparison of the time to initiation of AA solution, days of PN, the day of life enteral feeds were started, the day of life full feeds were achieved, the day of life birth weight was regained and weight at 32 weeks post menstrual age is reported in Table 2 . Infants started PN earlier in the early AA group compared with the standard PN group, although most infants in the standard PN group had PN initiated by 24 h of life. There were no differences between the groups in any of the other primary or secondary outcome variables.
Clinical adverse events, including chronic lung disease, direct hyperbilirubinemia or late sepsis, were also similar between the groups (Table 3) . Children who developed late sepsis in both groups were infected with a variety of pathogens. There were a total of 15 different bacteria or fungi cultured, with no predominance of any organism in one of the groups, with the most common being Staphylococcus epidermidis (n ¼ 11), Staphylococcus aureus (n ¼ 5) and Enterococcus cloacae (n ¼ 4). NEC occurred more frequently in the early AA group (12 vs 1%), despite the similarity in time to initiate and reach full feeds.
Discussion
In this pre-post intervention comparative study, early administration of AA was not associated with a decrease in total days of PN, the day of life full feeds were achieved or total days in the NICU. There has been a growing body of literature regarding the safety and efficacy of early AA administration in preterm neonates. [1] [2] [3] 11, 13 However, there is still wide variability in practice. Despite the lack of agreement on the ideal age at which to introduce AA to the feeding regimen of a preterm neonate, available data suggest that VLBW neonates require a daily minimum of 60 kcal kg À1 per day (including 1.5 g kg À1 per day of AA) to prevent catabolism, and 80 to 90 kcal kg À1 per day (including 3.5 g kg À1 per day of AA) to maintain the growth rate that they would have had in utero. [14] [15] [16] [17] [18] [19] Some studies have used a smaller amount of AA (less than or equal to 1.5 g kg À1 per day) given to ill preterm infants, beginning on the first day of life. 20, 21 The results showed improvement in whole-body protein balance as a result of increased protein synthesis. Other studies included infants with higher birth weights (mean birth weight 1.4 kg±0.2 kg). 21, 22 The administration of the AAs to these infants on the second day of life versus the fourth day of life resulted in a higher protein synthesis rate. The amount of AA in our study was higher (2.2 g kg À1 per day) and focused specifically on infants with lower birth weights. Overall, our practice change to a more aggressive administration of AA was well tolerated but was not associated with an improvement in growth.
Ehrenkranz et al. 23, 24 showed that infants, when supplied with adequate nutrition, approached the intrauterine growth rates for weight, length and head circumference after regaining birth weight. The researchers found that once VLBW infants regained birth weight, their average daily weight gain ranged between 14.4 and 16.1 g kg À1 per day, a rate similar to the reported intrauterine weight gain of 1.5% per day or 15 g kg À1 per day. [25] [26] [27] [28] In addition, their average weekly increments in length (0.9 cm per week) and head circumference (0.9 cm per week) were similar to the increases in the rates of intrauterine length and head circumference reported between 26 and 36 weeks of gestation (1.1 and 0.7 cm per week, respectively). 29 This is in contrast with previous studies, in which the sickest VLBW infants had poor weight gain and inadequate catch-up growth during the first few weeks of life. 30 These infants had improved whole-body protein balance but were started on less AA (1.5 g kg À1 per day of AA) in the first day of life.
In an additional study of more than 1000 infants born at 23 to 27 weeks, growth velocity was shown to be positively associated with nutritional practices on the seventh day of life. 31 Despite this, 75% of the infants had extrauterine growth restriction at day 28 of life. In our study, we did not find a difference in overall growth velocity in the two periods. The mean weight at 32 weeks was at the 25th percentile in both groups, using the longitudinal growth curves of the National Institute of Child Health and Human Development. The adequate growth in the standard PN group, and the increased incidence of NEC in the early AA group, may have made any improvement in growth velocity in the early AA group difficult to detect. a Some infants were transferred to an outside institution on oxygen before 28 days of life (n ¼ 3 in standard PN group, n ¼ 1 in early AA group) and were hence excluded. Early PN for VLBW infants J Trintis et al
Early administration of AAs to VLBW infants may significantly affect future health. Certainly, studies have shown that adequate head growth is associated with improved neurodevelopmental outcome. [7] [8] [9] In addition, better nutrition may aid in recovery from common neonatal complications, such as chronic lung disease and late sepsis. 10 A recent study by Stephens et al. 32 showed that ELBW infants had improved Mental Developmental Index scores at 18 months of age with higher protein intake in first week of life.
The strengths of this study include a larger sample size compared with previous studies, focusing on a high-risk group of neonates who were at lower gestational ages and birth weights. Despite this, there was no significant difference in time to regain birth weight and weight at 32 weeks post-menstrual age. Our standard practice included starting AA at an early age, with the majority of infants receiving PN with AA within the first 24 h of life. The small differences in time to start AA between the two time periods may explain the similarity of outcomes between the two groups.
Limitations of this study include a sample size that is too small to detect differences in all neonatal outcomes. In addition, the pre-and post-study design has the potential bias of including patients of different severity of illnesses. To account for this bias, we compared the Score for Neonatal Acute Physiology, Version II and lengths of stay between groups. Although many variables affect the scores and length of stay, we found no differences between the two groups. We did have a difference in the incidence of NEC for the two time periods. This does not seem to be a reflection of the change in administration of PN, as there was no difference in feeding practices observed in the two periods, and likely represents the episodic nature of NEC. The other limitation of the pre-and post-study includes changes in management policies over time. There were no major changes in policies or treatment strategies during the time frame studied. However, we cannot account for minor differences in clinical decisions.
Neonatal growth may have an effect that extends beyond the NICU. It has been suggested that impaired fetal and postnatal growth in term infants have been related to a higher risk of ischemic heart disease, impaired glucose tolerance and type II diabetes mellitus, and higher blood pressure later in life. 33, 34 These alarming observations have important implications for preterm infants who are at risk for postnatal growth failure. Long-term studies are needed to follow growth outcomes, neurodevelopmental outcomes and adult onset diseases after early, aggressive postnatal nutrition.
We are challenged to recognize the window of nutritional opportunity between the times of birth, when birth weight is regained, and when infants reach term corrected age. Specific strategies should be developed to target optimal nutrition during this important time frame.
